Financings Routine +

VVT Med Expands into the Dominican Republic, Appointing Antilles Medical as Exclusive Distributor

VVT Med Advances Global Commercial Rollout of ScleroSafe with Dominican Republic Entry and Tranche 2 Financing

By The Northwire Desk — AI Analysis Jun 11, 2026 · 08:30 TSXV: NaN

Executive Summary

VVT Med Inc. entered a Trial Distribution and Evaluation Agreement with Antilles Medical to exclusively distribute its ScleroSafe™ device in the Dominican Republic.
The agreement includes an initial purchase order from the distributor and establishes a defined pathway to a five-year exclusive partnership, contingent on mutual terms after the evaluation period.
Antilles Medical will handle local regulatory compliance, importation, and clinical training/certification for its staff.
The company confirmed completion of the first tranche of a non-brokered private placement: 4,262,654 units issued at $0.25 per unit for gross proceeds of $1,065,663.50.
Each unit contains one common share and one-half of a warrant exercisable at $0.375 for 24 months.
A second tranche on identical terms is planned to close on or about July 20, 2026.
Net proceeds will fund expanded U.S. and global commercialization, product manufacturing, working capital, and general corporate purposes.
Securities carry a four-month hold period per TSXV policy.
The announcement follows a series of commercial milestones: a major Italian distribution deal (April 27), first patient treatments in Italy (May 26), and peer-reviewed clinical data from India (April 30).

Material Impact

Commercial footprint: The Dominican Republic entry extends VVT Med's Americas network, complementing existing U.S., Indian, and South Korean partnerships. The trial nature and initial purchase order suggest low near-term revenue contribution.
Financing: The $1.065M gross from Tranche 1 and planned Tranche 2 provide incremental runway but are dilutive. The warrant structure ($0.375 exercise) indicates continued reliance on equity markets for capital.
Strategic execution: The company is systematically rolling out its NT-NT sclerotherapy platform across key markets. The progression from clinical validation (India) to commercial trials (Italy, DR) aligns with standard medtech commercialization playbooks.
Stock impact: Routine for a TSXV-stage medical device company. The market typically prices in these sequential distribution agreements and private placements as expected operational steps rather than fundamental re-raters.

TSXV: · Price

Company Overview

VVT Med Inc. develops and commercializes the ScleroSafe™ System, a non-thermal, non-tumescent (NT-NT) catheter-directed sclerotherapy device for treating venous disease (varicose and spider veins).
The technology enables controlled sclerosant delivery with simultaneous blood aspiration, eliminating the need for thermal energy or tumescent anesthesia.
The device holds FDA clearance and CE marking.
Commercial model relies on a hybrid approach: direct sales in the U.S. (notably through Northwell Health) and exclusive distribution partnerships internationally.
The company is in the early commercialization phase, scaling manufacturing and clinical adoption across multiple geographies.

More from NaN